Margenza

Chemical Namemargetuximab
Dosage FormInjection (intravenous; 250 mg/10 mL (25 mg/mL) in a single-dose vial)
Drug ClassReceptor antagonists
SystemFemale reproductive
CompanyMacroGenics, Inc.
Approval Year2020

Indication

  • Indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Last updated on 1/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Margenza (margetuximab) Prescribing Information.2020MacroGenics, Inc. Rockville, MD